Current status of antiangiogenic factors

British Journal of Haematology

Volumn 109, Issue 3, 2000, Pages 477-489

  Harris, A L ^a   Talks, K L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Angiogenesi; Antigiogenesis; Clinical trials; Hypoxia; Therapeutic target

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; AE 941; ALPHA INTERFERON; ALPHA2A INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; CGS 27023A; CILENGITIDE; CM 101; COMBRETASTATIN; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERLEUKIN 12; LEFLUNOMIDE; MARIMASTAT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; MS 1246; PRINOMASTAT; RAZOXANE; SQUALAMINE; SU 006668; SURAMIN; TANOMASTAT; THALIDOMIDE; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; ZD 0101; ZK 22584;

ANGIOGENESIS; CLINICAL TRIAL; DRUG ACTIVITY; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; HYPOXIA; MACROPHAGE; NEUROTOXICITY; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR SUPPRESSOR GENE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANOXIA; CLINICAL TRIALS; GENE THERAPY; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES;

EID: 0034125929     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.01864.x     Document Type: Review

References (151)

1. Aguayo, A., Kantarjian, H., Talpaz, M., Estey, E., Koller, C., Estrov, Z., Obrien, S., Keating, M., Barlogie, B. & Albitar, M. (1998) Increased angiogenesis in chronic myeloid leukemia and myelodysplastic syndromes (Abstract). Blood, 92 (suppl. 1), p. 607a.
2. Anandappa, S.Y., Winstanley, J.H.R., Leinster, S., Green, B., Rudland, P.S. & Barraclough, R. (1994) Comparative expression of fibroblast growth factor messenger RNAs in benign and malignant breast disease. British Journal of Cancer, 69, 772-776.
3. Andrade, S.P., Fan, T.P. & Lewis, G.P. (1987) Quantitative in vivo studies on angiogenesis in a rat sponge model. British Journal of Experimental Pathology 68, 755-766.
4. Arap, W., Pasqualini, R. & Ruoslahti, E. (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279, 377-380.
5. Arbiser, J.L., Moses, M.A., Fernandez, C.A., Ghiso, N., Cao, Y.H., Klauber, N., Frank, D., Brownlee, M., Flynn, E., Parangi, S., Byers, H.R. & Folkman, J. (1997) Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proceedings of the National Academy of Sciences of the United States of America, 94, 861-866.
6. Arora, N., Masood, R., Zheng, T., Cai, J., Smith, D.L. & Gill, P.S. (1999) Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Research, 59, 183-188.
7. Banks, R.E., Forbes, M.A., Kinsey, S.E., Stanley, A., Ingham, E., Walters, C. & Selby, P.J. (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. British Journal of Cancer, 77, 956-964.
8. Bellamy, W.T., Richter, L., Frutiger, Y. & Grogan, T.M. (1999) Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Research, 59, 728-733.
9. Ben-Av, P., Crofford, L.J., Wilder, R.L. & Hla, T. (1995) Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Letters, 372, 83-87.
10. Benjamin, L.E., Golijanin, D., Itin, A., Pode, D. & Keshet, E. (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. Journal of Clinical Investigation. 103, 159-165.
11. Bergers, G., Javaherian, K., Lo, K.M., Folkman, J. & Hanahan, D. (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science, 284, 808-812.
12. Bikfalvi, A. & Han, Z.C. (1994) Angiogenic factors are hematopoietic growth factors and vice versa. Leukemia, 8, 523-529.
13. Boehm, T., Folkman, J., Browder, T. & O'Reilly, M.S. (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390, 404-407.
14. Boehm, T., O'Reilly, M.S., Keough, K., Shiloach, J., Shapiro, R. & Folkman, J. (1998) Zinc-binding of endostatin is essential for its antiangiogenic activity. Biochemical and Biophysical Research Communications, 252, 190-194.
15. Borgstrom, P., Bourdon, M.A., Hillan, K.J., Sriramarao, P. & Ferrara, N. (1998) Neutralizing antivascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate, 35, 1-10.
16. Borset, M., HjorthHansen, H., Seidel, C., Sundan, A. & Waage, A. (1996) Hepatocyte growth factor and its receptor c-Met in multiple myeloma. Blood, 88, 3998-4004.
17. Borset, M., Seidel, C., HjorthHansen, H., Waage, A. & Sundan, A. (1999) The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. Leukemia and Lymphoma, 32, 249-256.
18. Boylan, M., Van Den Berg, H.W. & Lynch, M. (1998) The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen. Annals of Oncology, 9, 205-211.
19. Braddock, P.S., Hu, D.E., Fan, T.P.D., Stratford, I.J., Harris, A.L. & Bicknell, R. (1994) A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions. British Journal of Cancer, 69, 890-898.
20. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79, 1157-1164.
21. Brooks, P.C., Silletti, S., von Schalscha, T.L., Friedlander, M. & Cheresh, D.A. (1998) Disruption of angiogenesis by PEX, a non-catalytic metalloproteinase fragment with integrin binding activity. Cell, 92, 391-400.
22. Brown, L.F., Berse, B., Jackman, R.W., Tognazzi, K., Guidi, A.J., Dvorak, H.F., Senger, D.R., Connolly, J.L. & Schnitt, S.J. (1995) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Human Pathology, 26, 86-91.
23. Camussi, G., Montrucchio, G., Lupia, E., De Martino, A., Perona, L., Arese, M., Vercellone, A., Toniolo, A. & Bussolino, F. (1995) Platelet-activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism. Journal of Immunology, 154, 6492-6501.
24. Carmeliet, P., Dor, Y., Herbert, J.M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., Koch, C.J., Ratcliffe, P., Moons, L. Jain, R.K., Collen, D. & Keshert, E. (1998) Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature, 394, 485-490.
25. Carmeliet, P., Mackman, N., Moons, L., Luther, T., Gressens, P., VanVlaenderen, I., Demunck, H., Kasper, M., Breier, G., Evrard, P., Muller, M., Risau, W., Edgington, T. & Collen, D. (1996) Role of tissue factor in embryonic blood vessel development. Nature, 383, 73-75.
26. Cheresh, D.A. (1998) Death to a blood vessel, death to a tumor. Nature Medicine, 4, 395-396.
27. Ciardiello, F., Damiano, V., Bianco, R., Bianco, C., De Fontanini, G., Laurentiis, M., DePlacido, S., Mendelsohn, J., Bianco, A.R. & Tortora, G. (1996) Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. Journal of the National Cancer Institute, 88, 1770-1776.
28. Clapp, C., Martial, J.A., Guzman, R.C., Rentier-Delrue, F. & Weiner, R.I. (1993) The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology, 133, 1292-1299.
29. Cohen, J. (1999) Cancer therapy - behind the headlines of endostatin's ups and downs. Science, 283, 1250-1251.
30. Cox, A.D. & Der, C.J. (1997) Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochimica et Biophysica Acta Reviews on Cancer, 1333, F51 -F71.
31. Dachs, G.U., Patterson, A.V., Firth, J.D., Ratcliffe, P.J., Townsend, K.M.S., Stratford, I.J. & Harris, A.L. (1997) Targeting gene expression to hypoxic tumor cells. Nature Medicine, 3, 515-520.
32. D'Amato, R.J., Loughnan, M.S., Flynn, E. & Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 91, 4082-4085.
33. Dameron, K.M., Volpert, O.V., Tainsky, M.A. & Bouck, N. (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science, 265, 1582-1584.
34. Darland, D.C. & D'Amore, P.A. (1999) Blood vessel maturation: vascular development comes of age. Journal of Clinical Investigation, 103, 157-158.
35. Davis, S., Aldrich, T.H., Jones, P.F., Acheson, A., Compton, D.L., Jain, V., Ryan, T.E., Bruno, J., Radziejewski, C., Maisonpierre, P.C. & Yancopoulos, G.D. (1996) Isolation of angiopoietin-I. a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell, 87, 1161-1169.
36. Dhanabal, M., Ramchandran, R., Waterman, M.J.F., Lu, H., Knebelmann, B., Segal, M. & Sukhatme, V.P. (1999) Endostatin induces endothelial cell apoptosis. Journal of Biological Chemistry, 274, 11721-11726.
37. Dickinson, A.J., Fox, S.B., Persad, R.A., Hollyer, J., Sibley, G.N.A. & Harris, A.L. (1994) Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. British Journal of Urology, 74, 762-766.
38. Dirix, L.Y., Vermeulen, P.B., Pawinski, A., Prove, A., Benoy, I., De Pooter, C., Martin, M. & Van Oosterom, A.T. (1997) Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. British Journal of Cancer, 76, 238-243.
39. Ezekowitz, A., Mulliken, J. & Folkman, J. (1991) Interferon alpha therapy of hemangiomas in newborns and infants. British Journal of Haematology, 79, 67-68.
40. Ferrara, N. & Davis-Smyth, T. (1997) The biology of vascular endothelial growth factor. Endocrine Reviews, 18, 4-25.
41. Fiedler, W., Graeven, U., Ergun, S., Verago, S., Kilic, N., Stockschlader, M. & Hossfeld, D.K. (1997) Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood, 89, 1870-1875.
42. Figg, W.D., Raje, S., Bauer, K.S., Tompkins, A., Venzon, D., Bergan, R., Chen, A., Hamilton, M., Pluda, J. & Reed, E. (1999) Pharmacokinetics of thalidomide in an elderly prostate cancer population. Journal of Pharmaceutical Sciences, 88, 121-125.
43. Folkman, J. (1974) Tumor angiogenesis. Advances in Cancer Research, 19, 331-358.
44. Folkman, J. (1990) What is the evidence that tumors are angiogenesis dependent. Journal of the National Cancer Institute, 82, 4-6.
45. Folkman, J. & Klagsbrun, M. (1987) Angiogenic factors. Science, 235, 442-447.
46. Fotsis, T., Zhang, Y.M., Pepper, M.S., Adlercreutz, H., Montesano, R., Nawroth, P.P. & Schweigerer, L. (1994) The endogenous estrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor growth. Nature, 368, 237-239.
47. Fox, S.B., Gatter, K.C. & Harris, A.L. (1996) Tumour angiogenesis. Journal of Pathology, 179, 232-237.
48. Fox, S.B. & Harris, A.L. (1997) Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. Investigational New Drugs, 15, 15-28.
49. Fraterschroder, M., Risau, W., Hullmann, R., Gautschi, P. & Bohlen, P. (1987) Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proceedings of the National Academy of Sciences of the United States of America, 84, 5277-5281.
50. Furlong, R.A., Takehara, T., Taylor, W.G., Nakamura, T. & Rubin, J.S. (1991) Comparison of biological and immunochemical properties indicates that scatter factor and hepatocyte growth factor are indistinguishable. Journal of Cell Science, 100, 173-177.
51. Giatromanolaki, A., Koukourakis, M., Obyrne, K., Fox, S., Whitehouse, R., Talbot, D.C., Harris, A.L. & Gatter, K.C. (1996) Prognostic value of angiogenesis in operable non-small cell lung cancer. Journal of Pathology, 179, 80-88.
52. Gimbrone, Jr. M.A., Cotran, R.S., Leapman, S.B. & Folkman, J. (1974) Tumor growth and neovascularization: an experimental model using the rabbit cornea. Journal of the National Cancer Institute, 52, 413-427.
53. Goldman, C.K., Kendall, R.L., Cabrera, G., Soroceanu, L., Heike, Y., Gillespie, G.Y., Siegal, G.P., Mao, X.Z., Bett, A.J., Huckle, W.R., Thomas, K.A. & Curiel, D.T. (1998) Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proceedings of the National Academy of Sciences of the United States of America, 95, 8795-8800.
54. Good, D.J., Polverini, P.J., Rastinejad, F., Le Beau, M.M., Lemons, R.S., Frazier, W.A. & Bouck, N.P. (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proceedings of the National Academy of Sciences of the United States of America, 87, 6624-6628.
55. Gore, M., A'Hern, R., Stankiewicz, M. & Slevin, M. (1996) Tumour marker levels during marimastat therapy (Letter). Lancet, 348, 263.
56. Gu, Y.Z., Moran, S.M., Hogenesch, J.B., Wartman, L. & Bradfield, C.A. (1998) Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF-3α. Gene Expression, 7, 205-213.
57. Guillemin, K. & Krasnow, M.A. (1997) The hypoxic response: Huffing and HIFing. Cell, 89, 9-12.
58. Harris, A.L. (1997) Clinical trials of anti-vascular agent group B streptococcus toxin. Angiogenesis, 1, 36-37.
59. Hasinoff, B.B., Hellmann, K., Herman, E.H. & Ferrans, V.J. (1998) Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Current Medicinal Chemistry, 5, 1-28.
60. Hellerqvist, C.G., Thurman, G.B., Page, D.L., Wang, Y.F., Russell, B.A., Montgomery, C.A. & Sundell, H.W. (1993) Antitumor effects of GBS toxin: a polysaccharide exotoxin from group B beta-hemolytic streptococcus. Journal of Cancer Research and Clinical Oncology, 120, 63-70.
61. Hildenbrand, R., Dilger, I., Horlin, A. & Stutte, H.J. (1995) Urokinase plasminogen-activator induces angiogenesis and tumor vessel invasion in breast cancer. Pathology Research and Practice, 191, 403-409.
62. Hirschi, K.K. & D'Amore, P.A. (1996) Pericytes in the microvasculature. Cardiovascular Research, 32, 687-698.
63. Hjorth-Hansen, H., Seidel, C., Lamvik, J., Borset, M., Sundan, A. & Waage, A. (1999) Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukaemia. European Journal of Haematology, 62, 129-134.
64. Hockel, M., Schlenger, K., Hockel, S., Aral, B., Schaffer, U. & Vaupel, P. (1998) Tumor hypoxia in pelvic recurrences of cervical cancer. International Journal of Cancer, 79, 565-369.
65. Horak, E.R., Leek, R., Klenk, N., Lejeune, S., Smith, K., Stuart, N., Greenall, M., Stepniewska, K. & Harris, A.L. (1992) Angiogenesis, assessed by platelet endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet, 340, 1120-1124.
66. Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H. & Folkman, J. (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature, 348, 555-557.
67. Iurlaro, M., Vacca, A., Minischetti, M., Ribatti, D., Sardanelli, A., Giacchetta, F. & Dammacco, F. (1998) Antiangiogenesis by cyclosporin. Experimental Hematology, 26, 1215-1222.
68. Jiang, B.H., Agani, F., Passaniti, A. & Semenza, G.L. (1997) V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Research, 57, 5528-5335.
69. Jones, J.L. & Walker, R.A. (1997) Control of matrix metalloproteinase activity in cancer. Journal of Pathology, 183, 377-379.
70. Kaban, L.B., Mulliken, J.B., Ezekowitz, R.A., Ebb, D., Smith, P.S. & Folkman, J. (1999) Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics, 103, 1145-1149.
71. Kehinde, E.O., Terry, T.R., Mistry, N., Horsburgh, T., Sandhu, D.P. & Bell, P.R.F. (1995) UK studies on suramin therapy in hormone resistant prostate cancer. Cancer Surveys, 23, 217-229.
72. Kenyon, B.M., Browne, F. & Damato, R.J. (1997) Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Experimental Eye Research, 64, 971-978.
73. Kerbel, R.S., Viloria-Petit, A., Okada, F. & Rak, J. (1998) Establishing a link between oncogenes and tumor angiogenesis. Molecular Medicine, 4, 286-295.
74. Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S. & Ferrara, N. (1993) Inhibition of vascular endothelial growth factor-induced angiogcnesis suppresses tumor growth in vivo. Nature, 362, 841-844.
75. Kini, A.R., Peterson, L.C. & Kay, N.E. (1998) Evidence for abnormal angiogenesis in the bone marrow of patients with B-cell chronic lymphocytic leukemia (CLL). Blood, 92, 2947.
76. Kini, A.R., Tallman, M.S. & Peterson, L.C. (1999) Abnormal angiogenesis in the bone marrow of patients with hairy cell leukemia (HCL). Laboratory Investigation, 79, 819.
77. Klauber, N., Rohan, R.M., Flynn, E. & Damato, R.J. (1997a) Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nature Medicine, 3, 443-446.
78. Klauber, N., Parangi, S., Flynn, E., Hamel, E. & Damato, R.J. (1997b) Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Research, 57, 81-86.
79. Kohn, E.C., Reed, E., Sarosy, G., Christian, M., Link, C.J., Cole, K., Figg, W.D. Davis, P.A., Jacob, J., Goldspiel, B. & Liotta, L.A. (1996) Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Research, 56, 569-573.
80. Kong, H.-L. & Crystal, R.G. (1998) Gene therapy strategies for tumor antiangiogenesis. Journal of the National Cancer Institute, 90, 273-286.
81. Kudelka, A.P., Verschraegen, C.F. & Loyer, E. (1998) Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. New England Journal of Medicine, 338, 991-992.
82. Lin, P.N., Buxton, J.A., Acheson, A., Radziejewski, C., Maisonpierre, P.C., Yancopoulos, G.D., Thannon, K.M., Hale, L.P., Dewhirst, M.W., George, S.E. & Peters, K.G. (1998) Antiangiogenic gene therapy targeting the ondothelium-specific receptor tyrosine kinase Tie2. Proceedings o the National Academy of Sciences of the United States of America, 95, 8829-8834.
83. Maione, T.E., Gray, G.S., Petr. J., Hunt, A.J., Donner, A.L., Bauer, S.I., Carson, H.F. & Sharpe, R. (1990) Inhibition of angiogenesis by recombinant human plate et factor-4 and related peptides. Science, 247, 77-79.
84. Maisonpierre, P.C., Suri, C. Jones, P.E., Bartunkova, S., Wiegand, S., Radziejewski, C., Compton, D., McClain, J., Aldrich, T.H., Papadopoulos, N., Daly, T.J., Davis, S., Sato, T.N. & Yancopoulos, G.D. (1997) Angiopoietir -2, a natural antagonist for Tie2 that disrupts in vivo angiogen sis. Science, 277, 55-60.
85. Marshall, J.L., Wellstein, A., Rae, J., DeLap, R.J., Phipps, K., Hanfelt, J., Yunmbam, M.K., Sur, J.X., Duchin, K.L. & Hawkins, M.J. (1997) Phase I trial of ora ly administered pentosan polysulfate in patients with advanced cancer. Clinical Cancer Research, 3, 2347-2354.
86. Mauceri, H.J., Hanna, N.N., Beckett, M.A., Gorski, D.H., Staba. M.-J., Stellato, K.A., Bigelow, K. Heimann, R., Gately, S., Dhanabal, M., Soff, G.A., Sukhatme, V.P., Kufe, D.W. & Weichselbaum, R.R. (1998) Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature, 394, 287-291.
87. Maxwell, P.H., Dachs, G.U., Gleadle, J.M., Nicholls, L.G., Harris, A.L., Stratford, I.J., Hankinson O., Pugh, C.W. & Ratcliffe, P.J. (1997) Hypoxia-inducible factor- I modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 94, 8104-8109
88. Maxwell, P.H., Wiesener, M.S., Chang, G.W., Clifford, S.C., Vaux, E.C., Cockman, M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R. & Ratcliffe. P.J. (1999) The tumour suppressor protein VHL targets hypoxia inducible factors for oxygen dependent proteolysis. Nature, 399, 271-275.
89. Millauer, B., Longhi, M.P., Plate, K.H., Shawver, L.K., Risau, W., Ullrich, A. & Strawn, L.M. 1996) Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Research, 56, 1615-1620.
90. Min, H.Y., Doyle, L.V., Vitt, O.R., Zandonella, C.L., Stratton-Thomas, J.R., Shuman, M.A. & Rosenberg, S. (1996) Urokinase receptor antagonists inhibit angle genesis and primary tumor growth in syngeneic mice. Cancer Research, 56, 2428-2433.
91. Mitchell, C.A., Davies, M.J., Grounds, M.D., McGeachie, J.K., Crawford, G.J., Hong, Y. & Chirila, T.V. (1996) Enhancement of neovascularization in regenerating skeletal muscle by the sustained release of erucamide from a polymer matrix. Journal of Biomaterials Applications, 0, 230-249.
92. Moehler, T.M., Hawighorst, I., Max, R., Hegenbart, U., Knopp, M.V., van Kaick, G., Ho, A.D. & Goldschmidt, H. (1998) Monitoring of vascularity and blood vessel permeability in bone lesions of multiple myeloma by magnetic resonance imaging. Blood, 92, 405.
93. Moenner, M., Gusse, M., Hatzi, E. & Badet, J. (1994) The widespread expression of angiogenir in different human cells suggests a biological function not only related to angiogenesis. European Journal of Biochemistry, 225, 483-490.
94. Moghaddam, A., Zhang, H.T., Fan, T.P.D., Hu, D.E., Lees, V.C., Turley, H., Fox, S.B., Gatter, K.O., Harris, A.L. & Bicknell, R. (1995) Thymidine phosphorylas is angiogenic and promotes tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 92, 998-1002.
95. Montesano, R., Matsumoto K., Nakamura, T. & Orci, L. (1991) Identification of a fibroblast derived epithelial morphogen as hepatocyte growth factor. Cell, 67, 901-908.
96. Motzer, R.J., Schwartz, L., Law, T.M., Murphy, B.A., Huffman, A.D., Albino, A.P., Vlamis, V. & Nanus, D.M. (1995) Interferon alfa-2α and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. Journal of Clinical Oncology, 13, 1950-1957.
97. Munshi, N., Wilson, C.S., Penn, J., Epstein, J., Singhal, S., Hough, A., Sanderson, R., Desikan, R., Siegel, D., Mehta, J. & Barlogie, B. (1998) Angiogenesis in newly diagnosed multiple myeloma: poor prognosis with increased microvessel density (MVD) in bone marrow biopsies. Blood, 92, 400.
98. Ohlms, L.A., McGill, T.J.I., Jones, D.T. & Healy, G.B. (1994) Interferon alfa-2a therapy for airway hemangiomas. Annals of Otology Rhinology and Laryngology, 105, 1-8.
99. O'Reilly, M.S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W.S., Flynn, E., Birkhead, J.R., Olsen, B.R. & Folkman, J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-285.
100. O'Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M., Lane, W.S., Cao, Y.H., Sage, E.H. & Folkman, J. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79, 315-328.
101. Perez-Atayde, A.R., Sallan, S.E., Tedrow, U., Connors, S., Allred, E. & Folkman, J. (1997) Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. American Journal of Pathology 150, 815-821.
102. Pike, S.E., Yao, L., Jones, K.D., Cherney, B., Appella, E., Sakaguchi, K., Nakhasi, H., Teruya-Feldstein, J., Wirth, P., Gupta, G. & Tosato, G. (1998) Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. Journal of Experimental Medicine, 188, 2349-2356.
103. Rajkumar, S.V., Fonseca, R., Witzig, T.E., Gertz, M.A. & Greipp, P.R. (1999) Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia, 13, 469-472.
104. Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T. & Kerbel, R.S. (1995) Mutant ras oncogenes upregulate VEGF/ VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Research, 55, 4575-4580.
105. Raleigh, J.A., Calkins-Adams, D.P., Rinker, L.H., Ballenger, C.A., Weissler, M.C., Fowler, W.C., Novotny, D.B. & Varia, M.A. (1998) Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Research, 58, 3765-3768.
106. Relf, M., LeJeune, S., Scott, P.A.E., Fox, S., Smith, K., Leek, R., Moghaddam, A., Whitehouse, R., Bicknell, R. & Harris, A.L. (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Research, 57, 963-969.
107. Ribatti, D., Nico, B., Vacca, A., Marzullo, A., Calvi, N., Roncali, L. & Dammacco, F. (1998) Do mast cells help to induce angiogenesis in B-cell non-Hodgkin's lymphomas? British Journal of Cancer, 77, 1900-1906.
108. Ribatti, D., Vacca, A., Nico, B., Fanelli, M., Roncali, L. & Dammacco, F. (1996) Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. European Journal of Haematology, 56, 45-53.
109. Ribatti, D., Vacca, A., Nico, B., Quondamatteo, F., Ria, R., Minischetti, M., Marzullo, A., Herken, R., Roncali, L. & Dammacco, F. (1999) Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. British Journal of Cancer, 79, 451-455.
110. Risau, W. (1997) Mechanisms of angiogenesis. Nature, 386, 671-674.
111. Roberts, A.B., Sporn, M.B., Assoian, R.K., Smith, J.M., Roche, N.S., Wakefield, L.M., Heine, U.I., Liotta, L.A., Falanga, V., Kehrl, J.H. & Fauci, A.S. (1986) Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proceedings of the National Academy of Sciences of the United States of America, 83, 4167-4171.
112. Ryan, H.E., Lo, J. & Johnson, R.S. (1998) HIF-1α or is required for solid tumor formation and embryonic vascularization. EMBO Journal, 17, 3005-3015.
113. Sage, E.H. (1997) Pieces of eight: bioactive fragments of extracellular proteins as regulators of angiogenesis. Trends in Cell Biology, 7, 182-186.
114. Salceda, S. & Caro, J. (1997) Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox induced changes. Journal of Biological Chemistry, 272, 22642-22647.
115. Salgado, R., Vermeulen, P.B., Benoy, I., Weytjens, R., Huget, P., Van Marck, E. & Dirix, L.Y. (1999) Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. British Journal of Cancer, 80, 892-897.
116. Salven, P., Teerenhovi, H. & Joensuu, H. (1997) A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood, 90, 3167-3172.
117. Selinsky, B.S., Zhou, Z., Fojtik, K.G., Jones, S.R., Dollahon, N.R. & Shinnar, A.E. (1998) The aminosterol antibiotic squalamine permeabilizes large unilamellar phospholipid vesicles. Biochimica et Biophysica Acta Biomembranes, 1370, 218-234.
118. Semenza, G.L. & Wang, G.L. (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Molecular and Cellular Biology, 12, 5447-5454.
119. Shalaby, F., Rossant, J., Yamaguchi, T.P., Gertsenstein, M. Wu, X.-F., Breitman, M.L. & Schuh, A.C. (1995) Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice. Nature, 376, 62-66.
120. Shami, P.J., Hussong, J.W. & Rodgers, G.M. (1998) Evidence of increased angiogenesis in the bone marrow of patients with acute nonlymphocytic leukemia. Blood, 92, 2105.
121. Siemeister, G., Weindel, K., Mohrs, K., Barleon, B., Martiny-Baron, G. & Marme, D. (1996) Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Research, 56, 2299-2301.
122. Silva, H.T. & Morris, R.E. (1997) Leflunomide and malononitrilamides. American Journal of Medical Sciences, 313, 289-301.
123. Sin, N., Meng, L.H., Wang, M.Q.W., Wen, J.J., Bornmann, W.G. & Crews, C.M. (1997) The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proceedings of the National Academy of Sciences of the United States of America, 94, 6099-6103.
124. Singh, R.K., Gutman, M., Bucana, C.D., Sanchez, R., Llansa, N. & Fidler, I.J. (1995) Interferon alpha and interferon beta down regulate the expression of basic fibroblast growth factor in human carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 92, 4562-4566.
125. Singhal, S., Mehta, J., Eddlemon, P., Gray, P., Cromer, J. Desikan, R., Ayers, D., Siegel, D., Munshi, N., Anaissie, E., Kantarjian, H., Zeldis, J. & Barlogie, B. (1998) Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM). Blood, 92, 1-306.
126. Spencer, C.M. & Faulds, D. (1994) Paclitaxel a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs, 48, 794-847.
127. Stewart, R., Nelson, J. & Wilson, D.J. (1989) Epidermal growth factor promotes chick embryonicarcinogenesis. Cell Biology International Reports, 13, 957-965.
128. Suri, C., Jones, P.E., Patan, S., Bartunkova, S., Maisonpierre, P.C., Davis, S., Sato, T.N. & Yancopoulos, G.D. (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell, 87, 1171-1180.
129. Takahashi, Y, Kitadai, Y., Bucana, C.D., Cleary, K.R. & Ellis, L.M. (1995) Expression of vascular endothelial growth factor and its receptor, Kdr, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Research, 55, 3964-3968.
130. Takakura, N., Huang, X.L., Dumont, D., Yancopoulos, G.D. & Suda, T. (1998) TIE2-mediated interaction between hematopoietic cells and endothelial cells. Experimental Hematology, 26, 434.
131. Tian, H., McKnight, S.L. & Russell, D.W. (1997) Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes and Development, 11, 72-82.
132. Toi, M., Harris, A.L. & Bicknell, R. (1991) Interleukin-4 is a potent mitogen for capillary endothelium. Biochemical and Biophysical Research Communications, 174, 1287-1293.
133. Vacca, A., Diloreto, M., Ribatti, D., Distefano, R., Gadaleta-Caldarola, G., Iodice. G., Caloro, D. & Dammacco, F. (1995a) Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. American Journal of Hematology, 50, 9-14.
134. Vacca, A., Ribatti, D., Iurlaro, M., Albini, A., Minischetti, M., Bussolino, F., Pellegrino, A., Ria, R., Rusnati, M., Presta, M., Vincenti, V., Persico, M.G. & Dammacco, F. (1998) Human lymphoblastoid cells produce extracellular matrix degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. International Journal of Clinical and Laboratory Research, 28, 55-68.
135. Vacca, A., Ribatti, D., Roncali, L. & Dammacco, F. (1995b) Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Leukemia and Lymphoma, 20, 27-41.
136. Vacca, A., Ribatti, D., Ruco, L., Giacchetta, F. Nico, B., Quondamatteo, F., Ria, R., Iurlaro, M. & Dammacco, F. (1999) Angingenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. British Journal of Cancer, 79, 965-970.
137. Vacca, A., Ribatti, D., Roncali, L., Ranieri, G., Serio, G., Silvestris, F. & Dammacco, F. (1994) Bone marrow angiogenesis and progression in multiple myeloma. British Journal of Haematology, 87, 503-508.
138. Voest, E.E., Kenyon, B.B., Oreilly, M.S., Truitt, G., Damato, R.J. & Folkman, J. (1995) Inhibition of angiogenesis in vivo by interleukin-12. Journal of the National Cancer Institute, 87, 581-586.
139. Walther, M.M., Figg. W.D. & Linehan, W.M. (1996) Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder. World Journal of Urology, 14, S8-S11.
140. Wamil, B.D., Thurman, G.B., Sundell, H.W., DeVore, R.F., Wakefield, G., Johnson, D.H., Wang, Y.F. & Hellerqvist, C.G. (1997) Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial. Journal of Cancer Research and Clinical Oncology, 123, 173-179.
141. Weidner, N., Semple, J.P., Welch, W.R. & Folkman, J. (1991) Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. New England Journal of Medicine, 324, 1-8.
142. Wenger, R.H. & Gassmann, M. (1997) Oxygen(es) and the hypoxia inducible factor-I. Biological Chemistry, 378, 609-616.
143. Westermann, A.M., Dubbelman, R., Moolenaar, W.U., Beijnen, J. & Rodenhuis, S. (1997) Successful intraperitoneal suramin treatment of peritoneal mesothelioma. Annals of Oncology, 8, 801-802.
144. Wiesener, M.S., Turley, H., Allen, W.E., Willam, C., Eckardt, K.U., Talks, K.L., Wood, S.M., Gatter, K.C., Harris, A.L., Pugh, C.W., Ratcliffe, P.J. & Maxwell, P.H. (1998) Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1 α. Blood, 92, 2260-2268.
145. Wojtowicz-Praga, S.M., Dickson, R.B. & Hawkins, M.J. (1997) Matrix metalloproteinase inhibitors. Investigational New Drugs, 15, 61-75.
146. Yaccoby, S., Barlogie, B. & Epstein, J. (1998) Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92, 2908-2913.
147. Yao, L., Sgadari, C., Furuke, K., Bloom, E.T., Teruya-Feldstein, J. & Tosato, G. (1999) Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood, 93, 1612-1621.
148. Zetler, B.R. (1998) Angiogenesis and tumor metastasis. Annual Review of Medicine, 49, 407-424.
149. Zhang, H.T. & Harris, A.L. (1998) Anti-angiogenic therapies in cancer clinical trials. Expert Opinion Investigational Drugs. 7, 1629-1655.
150. Ziche, M., Maglione, D., Ribatti, D., Morbidelli, L., Lago, C.T., Battisti, M., Paoletti, I., Barra, A., Tucci, M., Parise, G., Vincenti, V., Granger, H.J., Viglietto, G. & Persico, M.G. (1997a) Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Laboratory Investigation, 76, 517-531.
151. Ziche, M., Morbidelli, L., Choudhuri, R., Zhang, H.T., Donnini, S., Granger, H.J. & Bicknell, R. (1997b) Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. Journal of Clinical Investigation, 99, 2625-2634.